Antisense & RNAi Therapeutics Market Report

Antisense & RNAi Therapeutics Market Analysis Report By Technology (siRNA, miRNA), By Application (Oncology, Cardiovascular, Neurodegenerative Disorder), By Route of Administration, And Segment Forecasts, 2018 - 2025

  • Published Date: Mar, 2018
  • Base Year for Estimate: 2016
  • Report ID: 978-1-68038-805-3
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 161

Industry Insights

The global antisense & RNAi therapeutics market size was estimated at USD 945.8 million in 2016 and is expected to witness a CAGR of 8.6% during the forecast period. Antisense technology offers an opportunity for manipulation of gene expression for the treatment of various diseases and this is expected to serve as a driving factor for R&D in this sector. This technology is used to study gene function for the purpose of disease management by regulating the expression of the disease-causing gene. This is also anticipated to fuel the progress of the market.

Japan antisense & RNAi therapeutics market

Antisense therapeutics enable highly specific and effective gene silencing and as a result, a fair number of gene silencing drugs are in the late stages of development. Presence of dozens of companies operating in this space indicates upcoming developments in this market. R&D for treatment of uncommon neurodegenerative diseases such as hereditary ATTR amyloidosis is also anticipated to boost growth.

Growing collaborations between pharmaceutical companies and companies providing drug delivery services are expected to be a high impact rendering growth factor. Development of antisense therapeutics for overcoming challenges such as unspecific modes of action and delivery-associated complications is also anticipated to fuel the market. 

In January 2016, Isis Pharmaceuticals announced the initiation of Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals for treatment of Hepatitis B. The impact of antisense technology is expected to increase dramatically with growing understanding between disease etiology, protein production, and genetics.

However, difficulty in delivering drugs to the desired site is a main challenge associated with the use of antisense and RNAi. Drug delivery to nervous tissues is one of the many problems as the drug has to pass the blood-brain barrier. Companies such as Isis Pharmaceuticals are working on developing methods of drug delivery to the brain by virtue of a catheter or tube, which is connected to the pump inserted in the chest.

Inevitable toxic effects is another roadblock in the usage of this technology. It is vital to determine the right dosage and composition of an antisense molecule to reduce HD symptoms and prevent the occurrence of side effects caused due to the alteration on the normal Huntington gene. Developments with respect to producing a personalized therapy based on antisense technology are anticipated to bolster growth in the coming years.

Technology Insights

Antisense RNA dominated the antisense & RNAi therapeutics market with the largest share owing to recent revival in interest pertaining to the usage of antisense oligonucleotides for the treatment of neurodegenerative disorders. Various approaches are being implemented for prevention of disease onset or halting progression.

Spinal muscular atrophy and amyotrophic lateral sclerosis are diseases that have been showing promising results with the use of antisense technology. In addition to this, many antisense oligonucleotides are being employed for treatment of non-neurodegenerative disorders. These include antisense-mediated exon skipping for Duchenne muscular dystrophy.

Application Insights

Rising demand for eradication of diseases such as HIV, cancer, and other mutating viral diseases is anticipated to influence the usage rate of oligonucleotide products. Increasing number of clinical trials for oligonucleotide drugs exhibits that the field is rapidly forwarding.

Oncology has emerged as a notable segment within the market. Presence of a substantial pipeline for cancer therapies by companies and institutes such as Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (ISIS Pharmaceuticals), and INSYS Therapeutics Inc. is expected to drive this segment’s potential over the coming years.

Global antisense & RNAi therapeutics market

In addition to this, R&D in nanocarriers for oligonucleotide delivery is anticipated to contribute positively to cancer management. These nanocarriers can be employed for minimizing toxicity. However, since nanoparticle systems are affected by inter- and intra-tumor heterogeneity, demand for efficient tumor targeting vectorization systems and multiple genes targeting oligonucleotide drugs is anticipated to increase in the coming years.

Route of Administration Insights

Rising incidence of liver disorders such as Hepatitis C and Hepatitis B is expected to drive demand for innovative therapeutic interventions such as RNAi therapeutics and antisense nucleotides. Liver seems an ideal target for evolving technologies and can be targeted easily by virtue of an intravenous route.

Moreover, a number of studies are being carried out for reduction of associated problems such as rapid drug elimination without desired pharmacological action. This is anticipated to drive R&D in the intravenous injections segment over the forecast period.

Regional Insights

North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.

Since the discovery of RNAi, there have been numerous avenues of treatment development using RNAi; however, the market has picked up very little over the past decade due to complexities in delivery methodologies related to RNAi. Development of newer nanotechnology-oriented methods has re-infused the market with high growth potential over the forecast period.

A number of drug candidates under clinical trials have shown favorable results and are progressing through the development phases. Assuming that such trials continue to show positive results, it can be expected that the North American market will witness considerable growth in demand over the forecast period.

Antisense & RNAi Therapeutics Market Share Insights

GSK, Sanofi-Genzyme, Alnylam Pharmaceuticals, Marina Biosciences, and Benitec Biopharma are some of the prominent players operating in this market. These players are involved in development of RNAi therapies and platforms that offer medicines, diagnostics, and personalized treatment options for key diseases.

Alnylam Pharmaceuticals, Isis Pharmaceuticals/ Ionis Pharmaceuticals, Quark Pharmaceuticals, and Gene Signal are companies with a stronger pipeline portfolio. Acquisition of major participants as well as prominent emerging players has been observed in order to maintain market dominance.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5-analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global antisense & RNAi therapeutics market report on the basis technology, application, route of administration, and region:

  • Technology Outlook (Revenue, USD Million, 2014 - 2025)

    • RNA Interference

      • siRNA

      • miRNA

    • Antisense RNA

  • Application Outlook (Revenue, USD Million, 2014 - 2025)

    • Oncology

    • Cardiovascular

    • Respiratory Disorders

    • Renal Diseases

    • Neurodegenerative Disorders

    • Genetic Disorders

    • Infectious Diseases

    • Other

  • Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

    • Pulmonary Delivery

    • Intravenous Injections

    • Intradermal Injections

    • Intraperitoneal Injections

    • Topical Delivery

    • Other Delivery Methods

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $7,950
Compass Access - $9,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified